Alder's migraine drug meets main goal in late-stage study
June 27, 2017 at 07:02 AM EDT
June 27 (Reuters) - Alder BioPharmaceuticals Inc said on Tuesday its experimental treatment to prevent episodic migraine met the main goal of reducing monthly migraine days in a late-stage study.